The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus

Internal Medicine

Volumn 57, Issue 15, 2018, Pages 2147-2156

  Sugiyama, Seigo ^a   Jinnouchi, Hideaki ^a,b   Kurinami, Noboru ^a   Hieshima, Kunio ^a   Yoshida, Akira ^a   Jinnouchi, Katsunori ^a   Nishimura, Hiroyuki ^a   Suzuki, Tomoko ^a   Miyamoto, Fumio ^a   Kajiwara, Keizo ^a   Jinnouchi, Tomio ^a  

^a Division of Cardiovascular Medicine Diabetes Care Center Jinnouchi Hospital   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Endothelial function; Fat mass; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ABDOMINAL SUBCUTANEOUS FAT; ADD ON THERAPY; ADIPONECTIN BLOOD LEVEL; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; ENDOTHELIAL DYSFUNCTION; FAT MASS; FEMALE; HUMAN; HYPEREMIA; INTRA-ABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; PERIPHERAL ARTERIAL TONOMETRY; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY; REACTIVE HYPEREMIA PERIPHERAL ARTERIAL TONOMETRY INDEX; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; ABDOMINAL FAT; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ABDOMINAL FAT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85051142952     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.0701-17     Document Type: Article

References (40)

1. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66: 255-270, 2015.
2. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020-1031, 2012.
3. Ribola FA, Cancado FB, Schoueri JH, De Toni VF, Medeiros VH, Feder D. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 21: 199-211, 2017.
4. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2: 911-922, 2014.
5. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12: 566-592, 2016.
6. Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as mono-therapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 5: 415-433, 2014.
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.
8. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.
9. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of dia-betes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752-772, 2016.
10. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13: 28, 2014.
11. Shigiyama F, Kumashiro N, Miyagi M, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol 16: 84, 2017.
12. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 16: 138, 2017.
13. Standl E, Schnell O, McGuire DK, Ceriello A, Ryden L. Integration of recent evidence into management of patients with athero-sclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 5: 391-402, 2017.
14. Matsuzawa Y, Sugiyama S, Sumida H, et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc 2: e000426, 2013.
15. Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. J Am Heart Assoc 4: e002270, 2015.
16. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 11: 61-74, 2010.
17. Matsuzawa Y, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelial function testing. Circ J 79: 685-694, 2015.
18. Jayawardene D, Ward GM, O’Neal DN, Theverkalam G, MacIsaac AI, MacIsaac RJ. New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering? Heart Lung Circ 23: 997-1008, 2014.
19. Kurinami N, Sugiyama S, Nishimura H, et al. Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus. Clin Drug Investig 38: 19-27, 2018.
20. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 146: 168-174, 2003.
21. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 77: 1337-1344, 2013.
22. Malavolti M, Mussi C, Poli M, et al. Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol 30: 380-391, 2003.
23. Kurinami N, Sugiyama S, Yoshida A, et al. Correlation of body muscle/fat ratio with insulin sensitivity using hyperinsulinemic-euglycemic clamp in treatment-naive type 2 diabetes mellitus. Diabetes Res Clin Pract 120: 65-72, 2016.
24. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 211: 283-286, 1999.
25. McCrea CE, Skulas-Ray AC, Chow M, West SG. Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design. Vasc Med 17: 29-36, 2012.
26. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium- glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6: 2017.
27. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-1772, 2009.
28. Stojanovic M, Prostran M, Radenkovic M. Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 72: 385-398, 2016.
29. Torimoto K, Okada Y, Mori H, et al. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol 14: 25, 2015.
30. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105: 141-150, 2014.
31. Look ARG, Gregg EW, Jakicic JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 4: 913-921, 2016.
32. Matsuzawa Y, Sugiyama S, Sugamura K, et al. Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients. Circ J 77: 2807-2815, 2013.
33. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 18: E1321, 2017.
34. Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med 3: 43, 2016.
35. Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res 15: 64-73, 2018.
36. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88: 4823-4831, 2003.
37. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoat-rophy and obesity. Nat Med 7: 941-946, 2001.
38. Zhang C, Luo H, Gao F, Zhang CT, Zhang R. A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program. Acta Diabetol 52: 625-628, 2015.
39. Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 13: 370-385, 2017.
40. Tanaka A, Shimabukuro M, Okada Y, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol 16: 48, 2017.